vs
NATIONAL HEALTH INVESTORS INC（NHI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是NATIONAL HEALTH INVESTORS INC的2.0倍（$207.3M vs $105.8M），NATIONAL HEALTH INVESTORS INC净利率更高（36.1% vs -62.0%，领先98.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 23.4%），NATIONAL HEALTH INVESTORS INC自由现金流更多（$-57.5M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 13.9%）
Oscar Health是美国营利性健康保险公司，2012年由约书亚·库什纳、凯文·纳泽米和马里奥·施洛瑟创立，总部位于纽约市。公司深耕健康保险领域，通过远程医疗、医疗专用技术界面及透明的理赔定价体系，降低患者的服务使用难度。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NHI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $105.8M | $207.3M |
| 净利润 | $38.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 36.1% | -62.0% |
| 营收同比 | 23.4% | 25.9% |
| 净利润同比 | -11.7% | 3.5% |
| 每股收益（稀释后） | $0.80 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $105.8M | $207.3M | ||
| Q3 25 | $89.8M | $159.9M | ||
| Q2 25 | $90.7M | $166.5M | ||
| Q1 25 | $89.3M | $139.3M | ||
| Q4 24 | $85.8M | $164.6M | ||
| Q3 24 | $82.9M | $139.5M | ||
| Q2 24 | $85.0M | $147.0M | ||
| Q1 24 | $81.5M | $108.8M |
| Q4 25 | $38.2M | $-128.6M | ||
| Q3 25 | $32.9M | $-180.4M | ||
| Q2 25 | $37.0M | $-115.0M | ||
| Q1 25 | $34.2M | $-151.1M | ||
| Q4 24 | $43.2M | $-133.2M | ||
| Q3 24 | $28.5M | $-133.5M | ||
| Q2 24 | $35.3M | $-131.6M | ||
| Q1 24 | $30.9M | $-170.7M |
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
| Q4 25 | 36.1% | -62.0% | ||
| Q3 25 | 36.6% | -112.8% | ||
| Q2 25 | 40.8% | -69.0% | ||
| Q1 25 | 38.3% | -108.5% | ||
| Q4 24 | 50.4% | -80.9% | ||
| Q3 24 | 34.4% | -95.7% | ||
| Q2 24 | 41.5% | -89.5% | ||
| Q1 24 | 38.0% | -156.8% |
| Q4 25 | $0.80 | $-1.28 | ||
| Q3 25 | $0.69 | $-1.81 | ||
| Q2 25 | $0.79 | $-1.17 | ||
| Q1 25 | $0.74 | $-1.57 | ||
| Q4 24 | $0.96 | $-1.34 | ||
| Q3 24 | $0.65 | $-1.40 | ||
| Q2 24 | $0.81 | $-1.52 | ||
| Q1 24 | $0.71 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.6M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $-80.0M |
| 总资产 | $2.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $19.6M | $421.0M | ||
| Q3 25 | $81.6M | $202.5M | ||
| Q2 25 | $18.6M | $176.3M | ||
| Q1 25 | $135.0M | $127.1M | ||
| Q4 24 | $24.3M | $174.0M | ||
| Q3 24 | $15.6M | $150.6M | ||
| Q2 24 | $14.8M | $480.7M | ||
| Q1 24 | $11.4M | $112.3M |
| Q4 25 | $1.5B | $-80.0M | ||
| Q3 25 | $1.5B | $9.2M | ||
| Q2 25 | $1.5B | $151.3M | ||
| Q1 25 | $1.4B | $144.2M | ||
| Q4 24 | $1.4B | $255.0M | ||
| Q3 24 | $1.2B | $346.8M | ||
| Q2 24 | $1.2B | $432.4M | ||
| Q1 24 | $1.2B | $140.3M |
| Q4 25 | $2.8B | $1.5B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.7B | $1.3B | ||
| Q1 25 | $2.8B | $1.3B | ||
| Q4 24 | $2.6B | $1.5B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B | ||
| Q1 24 | $2.5B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $236.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-57.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | -54.3% | -48.6% |
| 资本支出强度资本支出/营收 | 277.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 6.20× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $236.6M | $-99.8M | ||
| Q3 25 | $62.5M | $-91.4M | ||
| Q2 25 | $59.8M | $-108.3M | ||
| Q1 25 | $46.5M | $-166.5M | ||
| Q4 24 | $207.8M | $-79.3M | ||
| Q3 24 | $48.6M | $-67.0M | ||
| Q2 24 | $60.7M | $-77.0M | ||
| Q1 24 | $40.8M | $-190.7M |
| Q4 25 | $-57.5M | $-100.8M | ||
| Q3 25 | $-88.2M | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | $49.8M | $-79.5M | ||
| Q3 24 | $1.5M | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | -54.3% | -48.6% | ||
| Q3 25 | -98.2% | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | 58.1% | -48.3% | ||
| Q3 24 | 1.9% | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | 277.9% | 0.5% | ||
| Q3 25 | 167.8% | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | 184.2% | 0.1% | ||
| Q3 24 | 56.8% | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | 6.20× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.62× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 4.80× | — | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.72× | — | ||
| Q1 24 | 1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NHI
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
